Our Work
Latham & Watkins Advises Codagenix in US$25 Million Series B Extension Financing
February 17, 2023
Firm represents synthetic biology company in fundraising round.
Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral vaccines and immuno-oncology therapeutics, has announced the completion of a US$25 million Series B extension financing, with participation from a new investor, the Serum Institute of India Pvt. Ltd., along with existing investors Euclidean Capital and Adjuvant Capital.
Latham & Watkins LLP advised Codagenix in the financing with a corporate team led by Boston partner Spencer Ricks, with New York associates Eduard Grigoryan and Saem Kim.